Results of round 1 of the Delphi survey

Slides:



Advertisements
Similar presentations
HIV/AIDS situation in Serbia GORDANA J
Advertisements

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.
ARV failure and resistance for the paediatrician
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Evaluation of three 2 nd Line Antiretroviral regimens in Africa (Dakar, Yaounde) « 2 LADY » ANRS project.
VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.
Pre Test !!!!!!. How many classes of HIV meds are currently available?
2nd Line ART Considerations for Resource-Limited Settings
Terapia ARV u chorych z koinfekcją HIV/HBV/HCV – czy istnieją preferencyjne schematy ARV. Marek Beniowski.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
Case Discussion: HIV resistance and salvage regimens The 3 rd HIV-NAT Symposium Series Wasana Prasitsuebsai, MD, MPH 25 th July 2013.
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents December 2009 AETC NRC Slide Set.
Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.
Young person with multi-class resistance: follow-up and management (with perspectives from well-resourced and resource-limited settings) Gareth Tudor-Williams.
Switch to ATV + r-containing regimen - SWAN - SLOAT.
HIV Resistance Testing Clinical Implications Cyril K. Goshima, M.D. Director, AIDS Education Project June, 2009.
Antiretroviral Drugs in Pregnancy and Breastfeeding: Importance of Surveillance and Implications for Developing Countries Lynne M. Mofenson, M.D. Pediatric,
ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants  Considerations for choice of ARV drugs.
第 16 回日本エイズ学会 第 16 回日本エイズ学会 Interactive Session 症例から学ぶ HIV 感染症診療のコ ツ Michael S. Saag. 山元 泰之 青木 眞岩本 愛吉 座長 :
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
WHO - PSM 14/7/2005 Principles for selection of medicines Dr Mary R. Couper Quality Assurance and Safety of Medicines WHO.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Antiretroviral Therapy in Children With Drug Resistance Virus By Kulkanya Chokephaibulkit, MD Department of Pediatrics Faculty of Medicine Siriraj Hospital.
1 Research Advances in HIV Care Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine.
CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia.
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
The 2 nd International AIDS Society Conference on HIV Pathogenesis and Treatment July 13-16, 2003; Paris, France Selected and summarized by Douglas J.
Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere February 2006.
Current and Future Trends in HIV Therapy Hail M. Al-Abdely Consultant, Infectious Diseases.
Prevention and Care Dr S Charalambous WHO guidelines.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
AN OVERVIEW OF PHARMACOVIGILANCE OF HIV/AIDS IN NIGERIA
HAIVN Harvard Medical School AIDS Initiative in Vietnam
Long-Term Changes in Lipids and Glucose/Insulin among HIV-Infected Antiretroviral Naïve Persons Randomized to PI vs. NNRTI vs. PI+NNRTI-based strategies:
HIV in Brazil Daniela Zilio Larentis Infectious Disease Resident at HCPA.
Summary of PK studies thru 10/1/04* * Samples analyzed thru 5/30/04.
21st Century Therapy: Advances in Antiretroviral Options PROGRAM DIRECTOR Anton L. Pozniak, MD, FRCP Consultant Physician Department of HIV and Genitourinary.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
Modifying Antiretroviral Therapy to Improve Convenience in Patients With Virologic Suppression PROGRAM DIRECTOR Anton L. Pozniak, MD, FRCP Consultant Physician.
Switch to PI/r monotherapy
Antiretroviral Therapy (ART)
Optimizing Antiretorviral Therapy for Long-Term HIV Care
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202
TDF-FTC vs. ABC-3TC, each with Atazanavir + RTV or Efavirenz ACTG 5224s (Bone Effects): Study Design
XVI International AIDS Conference
Comprehensive Guideline Summary
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Marco Vitoria HIV Department Geneva
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Giới thiệu về điều trị ARV
Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV
Forecasting for ARVs medicines
ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.
Switch to DRV/r monotherapy
Switch to ATV- or ATV/r-containing regimen
Antiretroviral therapy and its complications
CASO CLINICO Il paziente naϊve ad alta viremia.
Comparison of PI vs PI ATV vs ATV/r BMS 089
CASO CLINICO Il paziente naϊve con resistenze al basale.
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Resistance in the age of Integrases
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Figure 1. Rate of PDR in infants according to ARV exposure
Dual vs. Triple ART: What to start?
Presentation transcript:

Results of round 1 of the Delphi survey Boniface Dongmo N. AMD Secretariat WHO Geneva

  2005 2006 2007 2008 2009 2010 Average 8% 7% 6% 5% 4% 3% Std Dev 0.05 0.04 1 Quartile 0.02 0.00 3 Quartile 0.10 0.09 0.08 Average - 1 STDEV 0.03 0.01 -0.01 Average + 1 STDEV 0.13 0.12 0.11

  2005 2006 2007 2008 2009 2010 Average 5% 7% 9% 11% 12% Std Dev 0.03 0.04 0.05 0.07 0.08 1 Quartile 0.02 0.06 3 Quartile 0.10 0.15 0.20 0.19 Average - 1 STDEV Average + 1 STDEV 0.11 0.14 0.17

  2005 2006 2007 2008 2009 2010 Average 0% 1% 2% 3% Std Dev 0.01 0.02 0.03 1 Quartile 0.00 3 Quartile 0.05 Average - 1 STDEV Average + 1 STDEV 0.04 0.06

  2005 2006 2007 2008 2009 2010 2 NRTI + 1 NNRTI 0.95 0.94 0.92 0.91 0.89 0.88 Triple NRTI 0.00 0.01 0.02 2NRTI + 1PI 0.04 0.05 0.06 0.08 0.10

  2005 2006 2007 2008 2009 2010 d4T 0.75 0.72 0.69 0.63 0.60 0.56 ZDV 0.20 0.30 0.31 0.34 0.35 0.37 TDF 0.03 0.05 0.08 0.10

  2005 2006 2007 2008 2009 2010 3TC 0.95 0.93 0.91 0.89 FTC 0.02 0.04 0.05 0.07

  2005 2006 2007 2008 2009 2010 EFV 0.24 0.25 0.28 0.30 0.31 0.32 NVP 0.78 0.75 0.72 0.70 0.69 0.67 ABC 0.00 ddI 0.01 ATV NFV 0.03 0.02 IDV LPV/r

  2005 2006 2007 2008 2009 2010 Sum of nucleoside estimates 1.32 1.37 1.40 1.43 Sum of PI estimate 0.94 0.95 0.97 1.00

  2005 2006 2007 2008 2009 2010 ddI 0.42 0.41 ABC 0.18 0.31 0.32 TDF 0.50 0.54 0.57 0.59 0.58 3TC 0.01 EFV 0.03 0.02 0.00 NVP ZDV 0.09 FTC 0.08 0.07 0.06

  2005 2006 2007 2008 2009 2010 IDV/r 0.13 0.14 0.12 LPV/r 0.37 0.44 0.47 0.50 0.49 NFV 0.31 0.28 0.27 0.26 SQV/r 0.07 ATV/r 0.00 0.01 0.02 0.03 0.05

  2005 2006 2007 2008 2009 2010 Production capacity D4T Low 18,959 30,652 41,040 48,652 58,391 67,657 222,000 High 30,334 54,588 82,257 103,825 123,994 134,771 ZDV 56,325 124,018 173,989 231,660 292,215 376,420 410,000 90,120 220,862 348,725 494,371 620,526 749,810 TDF 5,716 11,950 24,423 44,071 64,186 82,995 9,146 21,281 48,951 94,050 136,300 165,322 3TC 98,914 165,592 225,526 279,879 341,794 425,398 512,000 158,263 294,900 452,021 597,272 725,809 847,372 FTC 1,545 2,712 6,593 11,554 18,540 23,585 2,472 4,831 13,213 24,656 39,371 46,981 EFV 45,144 81,614 127,261 175,677 228,195 293,718 168,000 72,230 145,345 255,070 374,902 484,577 585,073 NVP 98,789 159,855 215,231 270,707 332,539 410,086 475,000 158,063 284,684 431,387 577,699 706,155 816,871 ABC 2,271 8,242 14,647 23,551 32,252 42,852 46,000 3,634 14,678 29,356 50,259 68,487 85,359 ddI 3,446 7,098 12,960 20,936 29,770 40,446 70,000 5,513 12,641 25,976 44,679 63,218 80,567 SQV 2,784 6,103 10,733 16,215 21,540 28,053 19,000 4,454 10,869 21,512 34,602 45,740 55,880 NFV 42,420 65,044 88,976 133,143 180,445 233,687 210,000 67,872 115,836 178,335 284,131 383,180 465,493 IDV 5,854 11,546 22,188 32,094 41,235 52,676 99,000 9,367 20,563 44,472 68,490 87,564 104,928 RTV 1,505 4,054 7,978 12,423 19,451 27,734 25,000 2,408 7,220 15,990 26,511 41,304 55,245 LPV/r 6,019 16,189 31,814 49,502 77,491 110,525 9,630 28,831 63,765 105,638 164,555 220,160